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Methods: Intravascular ultrasound (IVUS), fractional flow reserve (FFR), index of
microcirculatory resistance (IMR) and blood examination (CK-MB, cardiac troponin
(cTn) were performed in 82 consecutive patients with stable angina pectoris undergoing
PCI. FFR and IMR were measured with a single coronary pressure wire. IMR was defined
as Pd/coronary flow (or Pd * mean transit time) at peak hyperemia. Patients were
randomized to control (n40) or nicorandil groups (n42). In the nicorandil group,
nicorandil was intravenously administered as a 6-mg bolus injection just before PCI and
as a constant infusion at 6-mg/hour for 24-hours thereafter.
Results: All volumetric IVUS parameters and FFR were similar between the 2 groups
both pre and post PCI. However, patients treated with nicorandil had significantly lower
IMR immediately post PCI, and tended to have lower cTn 24-hours post PCI (IMR:
25.412.1 vs 17.99.1 units, p0.05, and cTn:0.210.13 vs 0.120.08 ng/mL,
p0.06, for control vs. nicorandil).Incidence of cTn elevation more than 5-fold of normal
range (0.15ng/mL) was significantly larger in the control group than in the nicorandil
group(41% vs. 12%, p0.01). The control group showed a closer correlation between
plaque volume reduction by IVUS and IMR than the nicorandil group(r0.48 vs. 0.40,
p0.001 for control vs. nicorandil).
Control Nicorandil p-value
Pre-Intervention
Lumen (mm2) 4.12 1.35 4.26 1.49 0.45
Vessel (mm2) 13.8 3.18 13.87 3.91 0.93
Plaque (mm2) 9.67 2.91 9.68 3.01 0.87
FFR 0.70 0.09 0.71 0.09 0.84
Post-Stent
Lumen (mm2) 8.18 1.75 8.22 2.02 0.92
Vessel (mm2) 16.73 3.32 16.7 4.11 0.97
Plaque (mm2) 8.58 2.23 8.57 2.71 0.99
FFR 0.93 0.1 0.91 0.10 0.53
Conclusions: In patients undergoing successful coronary stenting for stable angina,
administration of nicorandil is associated with reduced microvascular dysfunction induced
by PCI.
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Background: High density lipoprotein (HDL)-cholesterol may play an important role in
improving prognosis by cardio-protective effect. However, there are limited data whether
the improvement of HDL-C level by pitavastatin (Livalo®) in acute myocardial infarction
(AMI) patients (pts) can reduce cardiovascular events or not.
Methods: A total of 404 consecutive AMI pts underwent percutaneous coronary
intervention (PCI) with drug eluting stents (DES) from 10 major centers were divided into
two groups; the improved HDL-C group (n162) and the Control group (no improve-
ment in HDL-C level, n242). All pts were exclusively treated with pitavastatin
24mg/day from the onset of AMI. Improved HDL-C group was defined as increased
HDL-C/Total Cholesterol ratio and/or increased HDL-C level from index to 6 months
laboratory follow up. Major clinical outcomes up to 12 months were compared between
the two groups.
Results: Baseline clinical characteristics were similar between the two groups except the
improved HDL-C group showed higher level of triglyceride (146.8 vs. 111.8mg/dl,
p0.001) and lower HDL (39.7 vs. 50.3mg/dl, p0.001). Procedural success rate and in
hospital clinical outcomes were similar between the two groups. At 12 months, major
clinical outcomes were not different between the two groups (table).
Conclusions: In AMI pts undergoing PCI with DESs exclusively treated by pitavastatin,
improvements in HDL-C Level was not associated with better clinical outcomes.
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Background: The efficacy of beta-blockers (BBs) therapy in ST-elevation myocardial
infarction (STEMI) patients who underwent primary percutaneous coronary intervention
(PCI) is controversial. Moreover, the benefit of BBs therapy in hospital survivors who
underwent primary PCI has not been fully investigated.
Methods: Between November 2005 and January 2008, 2,688 hospital survivors who had
an STEMI with a symptom-to-door time of 12 hours and underwent primary PCI were
analyzed from the Korean Acute MI registry. Patients who received BBs therapy before
hospitalization were excluded from this study. The 12-month MACE was defined as a
composite of death, non-fatal MI, and revascularizations.
Results: Of these patients, BBs were used in 2,042 (76.0%) hospital survivors. Patients
receiving BBs were younger with less dyspnea at presentaion, higher body mass index,
longer symptom-to-door time, higher systolic and diastolic blood pressure, higher left
ventricular ejection fraction, and higher serum levels of glucose, total cholesterol, and
triglyceride. Ventricular arrhythmia during hospitalization was less frequently observed in
BBs patients. In Cox proportional-hazards model, there was no significant difference in
the 12-month MACE between BBs patients and no-BBs patients (9.9% versus 11.1%;
crude hazard ratio [HR] 0.864, 95% confidence interval [CI] 0.660–1.131; p0.287). The
12-month mortality was significantly lower in BBs patients compared with no-BBs
patients (2.0% versus 3.9%; crude HR 0.498, 95% CI 0.302–0.820; p0.006). Propensity
scores (PS) for BBs use was calculated for each of the patients, and was used to match 604
patients not receiving BBs with 604 patients receiving BBs. In Cox proportional-hazards
model, there were no significant differences in the rate of 12-month MACE (10.6% versus
10.3%; HR 1.030, 95%CI 0.726–1.460; p0.869) and mortality (2.8% versus 3.3%; HR
0.850, 95%CI 0.445–1.622; p0.621) between BBs and no-BBs patients.
Conclusions: The benefit of BBs therapy might be less cardioprotective in hospital
survivors with STEMI who underwent primary PCI. Further studies are required in these
patients.
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Background: Recently introduced oral antithrombotics, including apixaban, rivaroxa-
ban, and vorapaxar, has been developed as alternative to conventional antiplatelet regimen
for patients with acute coronary syndrome (ACS).
Methods: We searched MEDLINE, EMBASE, and Cochrane databases for randomized
controlled trials (RCTs) comparing the efficacy and safety of new oral antithrombotics to
standard antiplatelet regimen in patients with acute coronary syndrome. The primary
efficacy end point was the composite of cardiovascular death, myocardial infarction, or
stroke. Fixed-effects or Random-effects models were used to pool efficacy and safety data
across RCTs.
Results: Three studies, including 35,862 patients, were identified. Patients randomized to
a new oral antithrombotics had a decreased risk of the composite end point of
cardiovascular death, MI, or stroke (odds ratio [OR], 0.88; 95% confidence interval [CI],
0.82 to 0.94) and myocardial infarction (OR, 0.88; 95% CI, 0.80 to 0.95). Incidence of
ischemic stroke (OR, 0.81; 95% CI, 0.65 to 1.01) and stent thrombosis (OR, 0.81; 95%
CI, 0.66 to 1.00) tended to be lower in patients randomized to a new oral antithrombotic
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regimen. Randomization to a new oral antithrombotics was associated with a significantly
increased risk of major bleeding (OR, 1.99; 95% CI, 1.65 to 2.39).
Conclusions: In patients with ACS, the addition of new oral antithrombotic agent to
standard antiplatelet therapy significantly reduced the primary composite end point but
significantly increased the risk of major bleeding.
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Background: Aspirin and statin therapy are primary treatment strategies in patients with
cardiovascular disease. Heightened urinary 11-dehydrothromboxane B2(11-dTxB2) lev-
els have been associated with an increased risk of adverse cardiovascular events. The aim
of the study was to determine the effect of statin therapy on 11-dTxB2 levels in patients
undergoing coronary angiography on 325 mg aspirin.
Methods: Urinary 11-dTxB2 was measured in patients prior to coronary angiography
with (n155) and without (n95) statin therapy. Lipoproteins by vertical density gradient
ultracentrifugation technique and thrombin-induced platelet-fibrin clot strength(TIP-FCS),
a marker for cardiovascular events by thrombelastography, were also measured. The dose
dependent effect of statin therapy was analyzed according to atorvastatin equivalent dose,
categorized as: 5-10mg, 20-40mg, 80mg.
Results: Baseline demographics and cardiac risk factors were similar between groups.
Statins significantly reduced urinary 11-dTxB2 levels in a dose dependent manner
(Figure). There was a significant relation between quartiles of 11-dTxB2 and TIP-
FCS,(p0.05 for ANOVA). Patients on statin therapy had significantly lower levels of
LDL, triglycerides, VLDL, atherox and apo B100 (p0.005 for all). However, Urinary
11-dTxB2 did not correlate with lipids and lipoproteins measurements.
Conclusions: This is the first study to demonstrate the dose dependent response of statin
therapy on urinary 11-dTxB2 levels, independent of lipid lowering effects.Clinical
outcome studies are required to determine the utility of this novel marker for optimizing
statin therapy.
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Background: Fish Oil supplementation may have anti-atherosclerotic effects by reducing
triglycerides, improving endothelial function, and reducing inflammation. However,
inconsistent results have been reported on the effects of fish oil on platelet function. We
aimed to determine if fish oil supplementation reduced the atherothrombotic risk profile
by measuring lipids and thrombogenic factors simultaneously.
Methods: Patients with suspected coronary artery disease with (n79) and without
(n324) fish oil supplementation were enrolled in the Multi-Analyte, Thrombogenic, and
Genetic Markers of Atheroclerosis (MAGMA) study. The lipid profile was determined by
vertical density gradient ultracentrifugation technique, and thrombogenicity by thrombe-
lastography immediately prior to elective coronary angiography. Urinary 11-
dehydrothromboxane B2 and AtherOx were performed by immunoassay. ADP and collagen-
induced platelet aggregation were measured in aspirin	 clopidogrel- treated patients.
Results: Baseline demographics and cardiac risk factors were similar between groups.
Fish oil supplementation was associated with significantly lower triglycerides, VLDL,
remnant lipoproteins, and AtherOx levels and increased HDL levels (p0.05). Among
patients on aspirin 	 clopidogrel therapy, fish oil supplementation was associated with
lower collagen-induced platelet aggregation (p0.05, Table).
No Fish Oil
(n324)
Fish Oil
(n79)
p-valueMean  SD Mean SD
Lipid Profile (mg/dL)
Total cholesterol 16138 16252 0.85
Total low density lipoprotein 9330 9443 0.87
Total high density lipoprotein 4412 4917 0.03
Total very low density lipoprotein 2213 196 0.02
Triglycerides 12690 10357 0.05
Remnant lipoproteins 24.311 21.07.6 0.02
Thrombogenicity Profile
AtherOx (mg/dL) 0.420.48 0.290.27 0.05
Lipoprotein (a) (mg/dL) 8.66.3 8.46.0 0.82
11-dehydrothromboxane B2 (pg/
mg creatinine)
16331636 13301520 0.25
Clotting index 0.72.6 0.53.2 0.12
MAKH (mm) 66.66.1 65.54.5 0.21
R (min) 7.92.3 7.42.9 0.12
20uM ADP-induced aggregation 5220 4621 0.2
4ug/mL collagen-induced
aggregation
4822 3822 0.05
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